Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sentry Petroleum Ltd (SPLM)
Denver, CO, US
Sentry Petroleum Ltd. (SPLM) operates as an early-stage energy company, primarily focused on the acquisition, exploration, and development of oil and natural gas properties. The firm possesses a full 100% ownership interest in four distinct exploration permits, specifically ATPs 862, 864, 865, and 866. These substantial concessions collectively cover an expansive region of roughly 6.9 million net acres within Queensland's Adavale Basin. Founded in 2006, the company initially operated as Summit Exploration Inc. before rebranding to Sentry Petroleum Ltd. in December 2007. Its corporate headquarters are situated in Denver, Colorado.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -66.67% | -96.00% | -95.00% | -99.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-120.0% Q2'22: +98.5% (vs Q1'11)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q2'22: -6.9% (vs Q1'11)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.2% Q2'22: +153.3% (vs Q1'11)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q2'22: 0.00× (vs Q1'11)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2011 | Paul Boldy Chief Financial Officer and Director | — | — | — | 1.01M | — | — | 1.01M | 100.00% | ↗ |
| 2 | 2011 | Raj Rajeswaran President, CEO and Director | — | — | — | 574.8K | — | — | 574.8K | 100.00% | ↗ |
| 3 | 2011 | Arne Raabe Secretary and Director | — | — | — | 574.8K | — | — | 574.8K | 100.00% | ↗ |
| 4 | 2011 | Alan Hart Vice President of Exploration and Director | — | — | — | 344.9K | — | — | 344.9K | 100.00% | ↗ |
| 5 | 2011 | Heather Grant Former Secretary | — | — | — | — | — | 3.2K | 3.2K | 0.00% | ↗ |
| 6 | 2010 | Raj Rajeswaran President, CEO and Director | — | — | — | 108.0K | — | — | 108.0K | 100.00% | ↗ |
| 7 | 2010 | Arne Raabe Secretary and Director | — | — | — | 44.0K | — | — | 44.0K | 100.00% | ↗ |
| 8 | 2010 | Alan Hart Vice President of Exploration and Director | — | — | — | 43.2K | — | — | 43.2K | 100.00% | ↗ |
| 9 | 2010 | Heather Grant Former Secretary | — | — | — | 6.9K | — | 4.0K | 10.9K | 63.43% | ↗ |
| 10 | 2009 | Alan Hart Vice President of Exploration and Director | — | — | — | 9.8K | — | 15.0K | 24.8K | 39.52% | ↗ |
| 11 | 2009 | Raj Rajeswaran President, CEO and Director | — | — | — | 24.5K | — | — | 24.5K | 100.00% | ↗ |
| 12 | 2009 | Arne Raabe Secretary and Director | — | — | — | 9.8K | — | — | 9.8K | 100.00% | ↗ |
| 13 | 2009 | Heather Grant Former Secretary | — | — | — | 1.6K | — | 5.2K | 6.8K | 24.09% | ↗ |
| 14 | 2008 | Alan Hart Former President and Chief Executive Officer | 10.0K | — | — | — | — | — | 10.0K | 0.00% | ↗ |
| 15 | 2008 | Heather Grant Secretary | 6.0K | — | — | — | — | — | 6.0K | 0.00% | ↗ |
| 16 | 2007 | Heather Grant Secretary | 761.00 | — | — | — | — | — | 761.00 | 0.00% | ↗ |
| 17 | 2006 | Alan Hart President, Secretary, Treasurer | 30.0K | — | — | — | — | — | 30.0K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alan Hart | Director | — | male |
| Arne Raabe | Corporate Secretary and Director | — | male |
| Paul Boldy | Chief Financial Officer & Director | — | — |
| Sage Ellie | President, Chief Executive Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPLM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
